Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 1 董事會謹此衷心感謝李女士於任職期間對本公司作出之貢獻。 承董事會命 康聖環球基因技術有限公司 主席 黃士昂 香港，2025年8月28日 變更公司秘書、授權代表及法律程序代理人 康聖環球基因技術有限公司（「本公司」）董事會（「董事會」）謹此宣佈，李美儀女 士（「李女士」）已辭任(i)本公司之聯席公司秘書；(ii)香港聯合交易所有限公司 （「聯交所」）證券上市規則（「上市規則」）第3.05條所規定之本公司授權代表（「授權 代表」）；及(iii)上市規則第19.05(2)條及香港法例第622章公司條例第16部項下代 表本公司於香港接受送達法律程序文件及通知書之代理人（「法律程序代理人」）， 自2025年8月29日起生效。李女士已確認彼與董事會及本公司 ...

Core Viewpoint - 康圣环球 (09960.HK) is expected to report a net loss of approximately RMB 30 million to RMB 35 million for the first half of 2025, compared to a net profit of about RMB 10.5 million for the same period in 2024 [1] Financial Performance - The anticipated net loss is primarily due to a revenue decline of RMB 16.4 million, representing a 3.5% decrease compared to the first half of 2024 [1] - The company expects a loss of approximately RMB 10.15 million from fair value changes in its invested funds [1] - An estimated credit loss of RMB 8.42 million is anticipated related to accounts receivable from COVID-19 business [1] - The acquisition of Guangzhou Benchmark Medical Co., Ltd. and Guangzhou Kangcheng Weiye Biotechnology Co., Ltd. is expected to incur additional expenses and result in a combined loss of approximately RMB 16 million for the first half of 2025 [1] Business Stability - Despite the anticipated losses, the core business of the group remains stable when excluding the aforementioned factors [1]

盈利警告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9960） 1. 2025年上半年收入下降人民幣16.4百萬元，較2024年上半年下降3.5%。 2. 本公司所參投基金公允價值變動帶來的虧損金額約為人民幣1,015萬元。 3. 本公司於2025年上半年新計提與新冠業務相關的應收賬款預計信用損失金額 約為人民幣842萬元。 4. 對廣州市基準醫療有限責任公司及廣州康丞唯業生物科技有限公司（合稱「併 購附屬公司」）的併購導致新增費用及併購附屬公司2025年上半年虧損合計約 為人民幣1,600萬元。 股東及潛在投資者於買賣本公司股份時務請審慎行事。 承董事會命 康聖環球基因技術有限公司 主席 黃士昂 香港，2025年8月22日 截至本公告日期，董事會包括執行董事黃士昂醫生、涂贊兵先生及柴海節女士； 非執 ...

Core Viewpoint - 康圣环球 (09960.HK) is scheduled to hold a board meeting on August 28, 2025, to review and approve the interim results for the six months ending June 30, 2025 [1] Group 1 - The board meeting will focus on the group's interim performance [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 董事會召開日期 康聖環球基因技術有限公司（「本公司」及其附屬公司「本集團」）董事會（「董事 會」）茲通告謹定於二零二五年八月二十八日（星期四）舉行董事會會議，藉以考慮 及通過本集團截至二零二五年六月三十日止六個月的綜合中期業績及其發佈，以 及處理其他事項。 承董事會命 康聖環球基因技術有限公司 主席 黃士昂 Kindstar Globalgene Technology, Inc. 康聖環球基因技術有限公司 香港，二零二五年八月十四日 （於開曼群島註冊成立的有限公司） 於本公告日期，董事會包括執行董事黃士昂醫生、涂贊兵先生及柴海節女士；非 執行董事黃瑞瑨先生、彭偉先生及黃璐女士；以及獨立非執行董事姚尚龍博士、 夏新平博士及顧華明先生。 （股份代號：9960） ...

本月底法定/註冊股本總額： USD 500,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康聖環球基因技術有限公司 呈交日期: 2025年8月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09960 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.00025 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,0 ...

Group 1 - The core viewpoint of the article highlights that Kangsheng Global (09960) has been recognized as the "Best Strategic Investment Institution in Medical Health" by Haoyue Capital, reflecting the company's achievements in strategic investments [1] - The "Medical Health Investment Excellence List" has become an important benchmark for assessing market value and brand influence in the medical health investment industry, focusing on the activity level, transaction volume, return performance, and post-investment empowerment of investment institutions [1] - Since its listing, Kangsheng Global has focused on specialized testing services, particularly in hematology, neurology, and solid tumors, reinforcing its leading position in the industry through continuous R&D investment and market expansion [1] Group 2 - In June 2024, Kangsheng Global acquired an 11.38% stake in Beijing Bofurui Gene Diagnostic Technology Co., enhancing its core testing technology's penetration and influence in the transplant market [2] - In September 2024, the company acquired 100% of Guangzhou Benchmark Medical, quickly entering the major solid tumor testing market, particularly for lung and gastric cancers, and expanding its early screening and diagnosis product pipeline [2] - In June 2025, Kangsheng Global established a joint venture with Biostate AI to leverage data and AI technology for early screening and diagnosis, promoting development in the precision medicine sector [2] Group 3 - The Chinese medical health industry is experiencing a structural recovery in 2025, with Kangsheng Global committed to driving innovation and the synergistic development of technology and services [3] - The company aims to actively seek potential market targets, utilizing valuation gaps to integrate complementary technology firms, thereby enhancing its risk resilience and growth potential [3] - Through mergers and acquisitions, along with its own products and services, Kangsheng Global is forming a balanced strategy to navigate challenges and continue progressing [3]

Group 1 - The core viewpoint of the articles highlights the recognition of 康圣环球 (Kangsheng Global) as the "Best Strategic Investment Institution in Healthcare" by 浩悦资本 (Haoyue Capital), reflecting the company's achievements in strategic investments [1] - The "Healthcare Investment Excellence List" by Haoyue Capital has become an important benchmark for assessing market value and brand influence in the healthcare investment industry, focusing on the activity level, transaction volume, return performance, and post-investment empowerment of investment institutions [1] - 康圣环球 has maintained a leading position in specialized testing by focusing on hematology, neurology, and solid tumors, continuously expanding its business boundaries through R&D investment and market expansion to meet growing clinical demands [1] Group 2 - In June 2024, 康圣环球 acquired an 11.38% stake in Beijing Bofurui Gene Diagnostic Technology Co., enhancing its core testing technology's penetration and influence in the transplant market [2] - In September 2024, 康圣环球 acquired 100% of Guangzhou Benchmark Medical, quickly entering the major solid tumor testing market, particularly for lung and gastric cancers, and expanding its IVD product pipeline [2] - In June 2025, 康圣环球 established a joint venture with Biostate AI to leverage data and AI technology for early screening and diagnosis, promoting development in precision medicine [2] Group 3 - The Chinese healthcare industry is experiencing a structural recovery in 2025, with 康圣环球 focusing on innovation to drive the synergy between technology and services [3] - The company aims to identify potential market targets and utilize valuation gaps to integrate complementary technology firms, enhancing its risk resilience and growth potential [3] - 康圣环球 plans to adopt a dual-track approach through mergers and its own products and services, maintaining a balanced strategy in the face of challenges [3]

Core Viewpoint - The third-party medical testing industry in China has experienced significant growth, particularly during the pandemic, with a market size reaching 630.5 billion yuan in 2022, but is expected to return to pre-pandemic levels in 2023 and stabilize around 388.8 billion yuan in 2024 [1][6]. Group 1: Industry Definition and Business Model - Medical testing is a discipline that utilizes modern physical and chemical methods for clinical diagnosis and treatment [2]. - Independent clinical laboratories (ICLs), also known as third-party medical laboratories, operate independently of hospitals and are licensed by health authorities to provide clinical testing and pathology services [2]. Group 2: Current Development Status - The ICL industry in China began in the 1980s and has become an essential part of the healthcare system due to increasing demand and favorable policies [4]. - The number of ICLs has grown from fewer than 70 in 2009 to an estimated 2,800 by 2024, with projections of reaching 2,845 by 2025 [4]. Group 3: Market Size and Growth Projections - The market size for third-party medical testing services in China was 630.5 billion yuan in 2022, with a significant drop expected in 2023 as pandemic testing demands decrease [6]. - The projected market size for 2024 is 388.8 billion yuan, with special testing accounting for 189.3 billion yuan and general testing for 199.5 billion yuan [6]. - By 2025, the market is expected to grow to approximately 444.9 billion yuan, with special testing at 218.1 billion yuan and general testing at 226.8 billion yuan [6]. Group 4: Industry Chain Structure - The third-party medical testing industry relies on specialized medical services, acting as a substitute for traditional hospital testing departments [8]. - The upstream of the industry includes suppliers of medical devices and testing reagents, while the downstream consists of various healthcare institutions that increasingly outsource testing services [8]. Group 5: Competitive Landscape - The market is characterized by a concentration of major players, with KingMed and Dian Diagnostics holding a combined market share of 36.16% [15]. - KingMed leads the market with a 17.04% share, providing services to over 20,000 medical institutions across 31 provinces and regions [15]. - Smaller third-party testing institutions face challenges due to limited scale and capabilities, leading to market exit pressures since 2015 [15]. Group 6: Financial Performance of Key Players - In 2024, KingMed reported revenues of 6.627 billion yuan, Dian Diagnostics 4.520 billion yuan, and Aidi Kang 2.914 billion yuan, among others [18]. Group 7: Development Trends - The third-party medical testing sector is becoming increasingly important, with regulatory changes posing new challenges [20]. - The industry is expected to focus on technological upgrades and strategic partnerships to enhance profitability and service quality [20]. - Automation, platformization, and intelligence are emerging as key trends in the development of third-party medical laboratories [20].

Core Insights - Kindstar Global and Biostate AI have officially signed an agreement to establish a joint venture aimed at advancing AI-driven precision medical solutions globally, particularly in China [1] - The collaboration will leverage Kindstar Global's extensive clinical testing network covering over 3,000 hospitals in China and Biostate AI's innovative RNA sequencing and AI technology [2][3] - The joint venture will focus on developing innovative diagnostic solutions tailored to the clinical needs in China, enhancing Kindstar Global's leadership in the precision medicine sector [3][4] Company Overview - Kindstar Global is recognized as a leading clinical testing service provider in China, with a robust network that supports the integration of data, diagnostics, and AI [2] - Biostate AI aims to create an AI system that truly understands human biology, enabling personalized medical treatments based on real-time data analysis [2] - The joint venture will initially target five prevalent specialty diseases: autoimmune diseases, oral cancer, diabetes, lymphoma, and post-organ transplant management [4] Strategic Goals - The partnership is seen as a significant milestone in both companies' strategic development, combining Biostate AI's innovative capabilities in RNA sequencing and AI algorithms with Kindstar Global's market expertise [4] - The joint venture will focus on optimizing and validating Biostate AI's RNA sequencing technology for the Chinese population's disease spectrum [4] - The collaboration aims to create a leading global precision medical platform, providing efficient and accurate diagnostic tools for healthcare professionals and patients [4]